Detalhe da pesquisa
1.
The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8+ cytotoxic T-cell response.
Genes Dev
; 36(9-10): 582-600, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35654454
2.
Anti-tumor activity of a novel LAIR1 antagonist in combination with anti-PD-1 to treat collagen-rich solid tumors.
Mol Cancer Ther
; 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38648067
3.
ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis.
Mol Cancer Res
; 21(8): 779-794, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37255406
4.
ZEB1 is regulated by K811 acetylation to promote stability, NuRD complex interactions, EMT, and NSCLC metastasis.
Mol Cancer Res
; 2023 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37171981
5.
Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer.
J Clin Invest
; 133(17)2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37655662
6.
Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.
Front Immunol
; 14: 1161869, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37449205
7.
Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
Cancer Res
; 81(5): 1398-1412, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33402388
8.
Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer.
JCI Insight
; 6(17)2021 09 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34309585
9.
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
Nat Commun
; 12(1): 2606, 2021 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33972557
10.
Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma.
Cancer Prev Res (Phila)
; 14(3): 313-324, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33277316
11.
MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs.
Oncogene
; 39(43): 6719-6732, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32963352
12.
IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion.
Oncogene
; 39(37): 5979-5994, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32753652
13.
Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer.
Matrix Biol
; 91-92: 8-18, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32442601
14.
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
J Thorac Oncol
; 15(5): 777-791, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068166
15.
The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors.
Cells
; 9(1)2019 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31878283
16.
A novel ex vivo tumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in non-small cell lung cancer.
Sci Rep
; 9(1): 4819, 2019 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30894630
17.
Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer.
Cancers (Basel)
; 11(4)2019 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30986992
18.
ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer.
Nat Commun
; 10(1): 5125, 2019 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31719531
19.
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Sci Transl Med
; 11(483)2019 03 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30867319
20.
Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.
Cancers (Basel)
; 11(5)2019 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31137625